高原地区睡眠呼吸障碍特征及治疗的研究进展

谭璐; 唐向东

doi:10.12182/20230360506

高原地区睡眠呼吸障碍特征及治疗的研究进展

doi: 10.12182/20230360506

谭璐,
唐向东^,

四川大学华西医院睡眠医学中心（成都 610041）

基金项目: 国家自然科学基金（No. U21A200386，No. 82100107）资助

详细信息

通讯作者:
E-mail：2372564613@qq.com

计量
- 文章访问数: 2147
- HTML全文浏览量: 37
- PDF下载量: 72
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-16
- 修回日期: 2023-02-17
- 网络出版日期: 2023-03-22
- 刊出日期: 2023-03-20

Sleep-Disordered Breathing at High Altitude: Its Characteristics and Research Progress in Treatment

TAN Lu,
TANG Xiang-dong^,

Sleep Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China

More Information

Corresponding author: E-mail: 2372564613@qq.com

摘要

摘要: 高原地区低压性低氧会增加睡眠呼吸障碍的发生风险。高原睡眠呼吸障碍主要是指高原人群和低海拔人群在高原地区出现的睡眠呼吸障碍，这两类人群也是目前高原睡眠呼吸障碍的研究重点。一方面，高原人群呼吸障碍的患病率和严重程度均高于低海拔人群，并且在转移到低海拔地区后会出现呼吸暂停时间的延长；另一方面，低海拔人群转移到高原地区后睡眠呼吸障碍的严重程度增加，主要以中枢型事件和低通气事件增加为主。在治疗方面，目前较多研究均发现，药物（包括乙酰唑胺和地塞米松）治疗和夜间氧疗均能改善低海拔地区人群在高原地区睡眠呼吸障碍的严重程度，但目前关于高原人群睡眠呼吸障碍治疗的研究较少，仅有研究发现夜间氧疗是可供选择的治疗措施。本文对高原睡眠呼吸障碍的研究进展进行综述，为未来进一步探讨高原人群睡眠呼吸障碍特征及治疗措施提供基础。
- 高原地区 /
- 阻塞性睡眠呼吸暂停 /
- 中枢型睡眠呼吸暂停 /
- 治疗
Abstract: Hypobaric hypoxia in regions of high altitude may increase the risk of having sleep-disordered breathing (SDB). SDB at high altitude mainly refers to the SDB incurred in highlanders and lowlanders at a high altitude. At present, research on SDB at high altitude is mainly focused on these two groups of people. On the one hand, highlanders have SDB at a higher prevalence and greater severity than lowlanders do and highlanders have a prolonged duration of apnea when they travel to low-altitude regions. On the other hand, the severity of SDB increased in lowlanders when they travel to high altitude, represented mainly by an increase in central and hypopnea events. In terms of treatment, a substantial number of studies have shown that medication, including acetazolamide and dexamethasone, and nocturnal oxygen supplementation could improve SDB in lowlanders when they travel to high altitude. However, not much research has been done on the treatment of SDB in highlanders and it has only been reported that nocturnal oxygen supplementation was an available treatment option. Herein, we summarized the latest research findings on SDB at high altitude, providing the basis for further studies about the characteristics and treatments for highlanders with SDB.
- High altitude /
- Obstructive sleep apnea /
- Central sleep apnea /
- Treatment

HTML全文

参考文献(51)

[1]	VEASEY S C, ROSEN I M. Obstructive sleep apnea in adults. N Engl J Med,2019,380(15): 1442–1449. doi: 10.1056/NEJMcp1816152
[2]	LAVIE P, HERER P, HOFFSTEIN V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ,2000,320(7233): 479–482. doi: 10.1136/bmj.320.7233.479
[3]	HOU H, ZHAO Y, YU W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health,2018,8(1): 010405. doi: 10.7189/jogh.08.010405
[4]	SANCHEZ-De-La-TORRE M, CAMPOS-RODRIGUEZ F, BARBE F. Obstructive sleep apnoea and cardiovascular disease. Lancet Respir Med,2013,1(1): 61–72. doi: 10.1016/S2213-2600(12)70051-6
[5]	TORRES G, SANCHEZ-De-La-TORRE M, BARBE F. Relationship between OSA and hypertension. Chest,2015,148(3): 824–832. doi: 10.1378/chest.15-0136
[6]	ECKERT D J, JORDAN A S, MERCHIA P, et al. Central sleep apnea: pathophysiology and treatment. Chest,2007,131(2): 595–607. doi: 10.1378/chest.06.2287
[7]	BURGESS K R, JOHNSON P L, EDWARDS N. Central and obstructive sleep apnoea during ascent to high altitude. Respirology,2004,9(2): 222–229. doi: 10.1111/j.1440-1843.2004.00576.x
[8]	SIMANCAS-RACINES D, AREVALO-RODRIGUEZ I, OSORIO D, et al. Interventions for treating acute high altitude illness. Cochrane Database Syst Rev,2018,6: CD009567. doi: 10.1002/14651858.CD009567.pub2
[9]	BEALL C M, DECKER M J, BRITTENHAM G M, et al. An Ethiopian pattern of human adaptation to high-altitude hypoxia. Proc Natl Acad Sci U S A,2002,99(26): 17215–17218. doi: 10.1073/pnas.252649199
[10]	BEALL C M, LASKOWSKI D, ERZURUM S C. Nitric oxide in adaptation to altitude. Free Radic Biol Med,2012,52(7): 1123–1134. doi: 10.1016/j.freeradbiomed.2011.12.028
[11]	SCHWARTZ N G, RATTNER A, SCHWARTZ A R, et al. Sleep disordered breathing in four resource-limited settings in Peru: prevalence, risk factors, and association with chronic diseases. Sleep,2015,38(9): 1451–1459. doi: 10.5665/sleep.4988
[12]	PHAM L V, MEINZEN C, ARIAS R S, et al. Cross-sectional comparison of sleep-disordered breathing in native Peruvian highlanders and lowlanders. High Alt Med Biol,2017,18(1): 11–19. doi: 10.1089/ham.2016.0102
[13]	REXHAJ E, RIMOLDI S F, PRATALI L, et al. Sleep-disordered breathing and vascular function in patients with chronic mountain sickness and healthy high-altitude dwellers. Chest,2016,149(4): 991–998. doi: 10.1378/chest.15-1450
[14]	TAN L, LI T, LUO L, et al. The characteristics of sleep apnea in Tibetans and Han long-term high altitude residents. Nat Sci Sleep,2022,14: 1533–1544. doi: 10.2147/NSS.S371388
[15]	HILL C M, CARROLL A, DIMITRIOU D, et al. Polysomnography in Bolivian children native to high altitude compared to children native to low altitude. Sleep,2016,39(12): 2149–2155. doi: 10.5665/sleep.6316
[16]	DUENAS-MEZA E, BAZURTO-ZAPATA M A, GOZAL D, et al. Overnight polysomnographic characteristics and oxygen saturation of healthy infants, 1 to 18 months of age, born and residing at high atitude (2, 640 Meters). Chest,2015,148(1): 120–127. doi: 10.1378/chest.14-3207
[17]	ALFORD N J, FLETCHER E C, NICKESON D. Acute oxygen in patients with sleep apnea and COPD. Chest,1986,89(1): 30–38. doi: 10.1378/chest.89.1.30
[18]	ALI N J, DAVIES R J, FLEETHAM J A, et al. The acute effects of continuous positive airway pressure and oxygen administration on blood pressure during obstructive sleep apnea. Chest,1992,101(6): 1526–1532. doi: 10.1378/chest.101.6.1526
[19]	PHILLIPS B A, SCHMITT F A, BERRY D T, et al. Treatment of obstructive sleep apnea. A preliminary report comparing nasal CPAP to nasal oxygen in patients with mild OSA. Chest,1990,98(2): 325–330. doi: 10.1378/chest.98.2.325
[20]	MILLS P J, KENNEDY B P, LOREDO J S, et al. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol (1985),2006,100(1): 343–348. doi: 10.1152/japplphysiol.00494.2005
[21]	TAN L, LI T, ZHANG Y, et al. Effect of one night of nocturnal oxygen supplementation on highland patients with OSA: a randomized, crossover trial. Chest,2021,160(2): 690–700. doi: 10.1016/j.chest.2021.02.046
[22]	TAN L, LI T, LEI F, et al. Longer apnea duration at low altitude in Tibetan and Han highlanders compared with Han lowlanders: a retrospective study. J Sleep Res,2019,29(2): e12934. doi: 10.1111/jsr.12934
[23]	PATZ D, SPOON M, CORBIN R, et al. The effect of altitude descent on obstructive sleep apnea. Chest,2006,130(6): 1744–1750. doi: 10.1378/chest.130.6.1744
[24]	BENJAMIN H H, JOHN T B, DAVID G I, et al. The impact of altitude on sleep-disordered breathing in children dwelling at high altitude. Sleep,2017,40(9): zsx120. doi: 10.1093/sleep/zsx120
[25]	PATZ D S, SWIHART B, WHITTE D P. CPAP pressure requirements for obstructive sleep apnea patients at varying altitudes. Sleep,2010,33(5): 715–718. doi: 10.1093/sleep/33.5.715
[26]	BLOCH K E, LATSHANG T D, TURK A J, et al. Nocturnal periodic breathing during acclimatization at very high altitude at Mount Muztagh Ata (7, 546 m). Am J Respir Crit Care Med,2010,182(4): 562–568. doi: 10.1164/rccm.200911-1694OC
[27]	LATSHANG T D, Lo CASCIO C M, STOWHAS A C, et al. Are nocturnal breathing, sleep, and cognitive performance impaired at moderate altitude (1,630-2,590 m)? Sleep,2013,36(12): 1969–1976. doi: 10.5665/sleep.3242
[28]	NUSSBAUMER-OCHSNER Y, SCHUEPFER N, ULRICH S, et al. Exacerbation of sleep apnoea by frequent central events in patients with the obstructive sleep apnoea syndrome at altitude: a randomised trial. Thorax,2010,65(5): 429–435. doi: 10.1136/thx.2009.125849
[29]	LATSHANG T D, TARDENT R P M, FURIAN M, et al. Sleep and breathing disturbances in patients with chronic obstructive pulmonary disease traveling to altitude: a randomized trial. Sleep,2019,42(1): zsy203. doi: 10.1093/sleep/zsy203
[30]	GAVLAK J C, STOCKS J, LAVERTY A, et al. The Young Everest Study: preliminary report of changes in sleep and cerebral blood flow velocity during slow ascent to altitude in unacclimatised children. Arch Dis Child,2013,98(5): 356–362. doi: 10.1136/archdischild-2012-302512
[31]	KOHLER M, KRIEMLER S, WILHELM E M, et al. Children at high altitude have less nocturnal periodic breathing than adults. Eur Respir J,2008,32(1): 189–197. doi: 10.1183/09031936.00119807
[32]	LI T, TAN L, FURIAN M, et al. Sex-specific difference in the effect of altitude on sleep and nocturnal breathing in young healthy volunteers. J Clin Med,2022,11(10): 2869. doi: 10.3390/jcm11102869
[33]	LOMBARDI C, MERIGGI P, AGOSTONI P, et al. High-altitude hypoxia and periodic breathing during sleep: gender-related differences. J Sleep Res,2013,22(3): 322–330. doi: 10.1111/jsr.12012
[34]	ERBA P, ANASTASI S, SENN O, et al. Acute mountain sickness is related to nocturnal hypoxemia but not to hypoventilation. Eur Respir J,2004,24(2): 303–308. doi: 10.1183/09031936.04.00006504
[35]	CLARENBACH C F, SENN O, CHRIST A L, et al. Lung function and breathing pattern in subjects developing high altitude pulmonary edema. PLoS One,2012,7(7): e41188. doi: 10.1371/journal.pone.0041188
[36]	LIU H M, CHIANG I J, KUO K N, et al. The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis. Ther Adv Respir Dis,2017,11(1): 20–29. doi: 10.1177/1753465816677006
[37]	NUSSBAUMER-OCHSNER Y, LATSHANG T D, ULRICH S, et al. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest,2012,141(1): 131–138. doi: 10.1378/chest.11-0375
[38]	LATSHANG T D, NUSSBAUMER-OCHSNER Y, HENN R M, et al. Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. JAMA,2012,308(22): 2390–2398. doi: 10.1001/jama.2012.94847
[39]	SCHMICKL C N, LANDRY S A, ORR J E, et al. Acetazolamide for OSA and central sleep apnea: a comprehensive systematic review and meta-analysis. Chest,2020,158(6): 2632–2645. doi: 10.1016/j.chest.2020.06.078
[40]	PARATI G, AGOSTONI P, BASNYAT B, et al. Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: a joint statement by the European Society of Cardiology, the council on hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine. Eur Heart J,2018,39(17): 1546–1554. doi: 10.1093/eurheartj/ehx720
[41]	ESKANDARI D, ZOU D, GROTE L, et al. Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a randomized controlled trial. J Clin Sleep Med,2018,14(3): 309–317. doi: 10.5664/jcsm.6968
[42]	CARAVITA S, FAINI A, LOMBARDI C, et al. Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. Chest,2015,147(1): 120–131. doi: 10.1378/chest.14-0317
[43]	ZHENG C R, CHEN G Z, YU J, et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. Am J Med,2014,127(10): 1001–1009.e2. doi: 10.1016/j.amjmed.2014.04.012
[44]	MAGGIORINI M, BRUNNER-LA ROCCA H P, PETH S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med,2006,145(7): 497–506. doi: 10.7326/0003-4819-145-7-200610030-00007
[45]	FURIAN M, LICHTBLAU M, AESCHBACHER S S, et al. Effect of dexamethasone on nocturnal oxygenation in lowlanders with chronic obstructive pulmonary disease traveling to 3100 meters: a randomized clinical trial. JAMA Netw Open,2019,2(2): e190067. doi: 10.1001/jamanetworkopen.2019.0067
[46]	NUSSBAUMER-OCHSNER Y, SCHUEPFER N, URSPRUNG J, et al. Sleep and breathing in high altitude pulmonary edema susceptible subjects at 4, 559 meters. Sleep,2012,35(10): 1413–1421. doi: 10.5665/sleep.2126
[47]	MORAGA F A, JIMENEZ D, RICHALET J P, et al. Periodic breathing and oxygen supplementation in Chilean miners at high altitude (4200 m). Respir Physiol Neurobiol,2014,203: 109–115. doi: 10.1016/j.resp.2014.09.001
[48]	WINDSOR J S, RODWAY G W. Supplemental oxygen and sleep at altitude. High Alt Med Biol,2006,7(4): 307–311. doi: 10.1089/ham.2006.7.307
[49]	TAN L, LATSHANG T D, AESCHBACHER S S, et al. Effect of Nocturnal oxygen therapy on nocturnal hypoxemia and sleep apnea among patients with chronic obstructive pulmonary disease traveling to 2048 meters: a randomized clinical trial. JAMA Netw Open,2020,3(6): e207940. doi: 10.1001/jamanetworkopen.2020.7940
[50]	PATRICIAN A, ENGAN H, LUNDSTEN D, et al. The effect of dietary nitrate on nocturnal sleep-disordered breathing and arterial oxygen desaturation at high altitude. High Alt Med Biol,2018,19(1): 21–27. doi: 10.1089/ham.2017.0039
[51]	BURGESS K R, LUCAS S J, SHEPHERD K, et al. Worsening of central sleep apnea at high altitude-a role for cerebrovascular function. J Appl Physiol (1985),2013,114(8): 1021–1028. doi: 10.1152/japplphysiol.01462.2012